CNC at a glance
Centene Corporation (CNC, SEC CIK 1071739) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as October 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Centene Corporation (CNC) reported revenue of $174.6 billion (up 20.0% from FY2024) and a net loss of $6.7 billion. Diluted EPS was -$13.53.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Centene Corporation (CNC) shares worth $15.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KOSTER CHRISTOPHER on August 26, 2026 of 56,500 shares at $66.90 per share.
- In the last 90 days, CNC insiders reported 0 open-market purchases ($0) and 1 open-market sale ($3.8M) on Form 4, a net sale of $3.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $174.6B
- +20.0% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$3.8M
- 13F holders
- 38 funds
- $15.1B · −1 vs prior quarter
- Latest 8-K
- Oct 27, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- CMS audit intensification risk with expanded risk adjustment data validation audits since 2025, potentially causing premium refunds and reducing revenue materially
- Texas and Georgia Medicaid reprocurement loss risk, involving protests due to unsuccessful bidding, threatening contract renewals and associated revenues
- Elevated medical cost risk from 2025 Marketplace membership with unexpectedly higher morbidity reducing net risk adjustment revenue significantly
- Part D bid risk from IRA-induced increased costs and enrollment volatility, with PDP membership boosted to 8.7 million in 2026 due to below-benchmark bids
- Medicare Advantage Star ratings risk with 40% of membership below 3.5 stars and contract terminations notices for 2025 impacting profitability and contract retention
Business Overview
- Core business model not directly described; document is primarily governance and regulatory disclosures
- No new products, services, or segments introduced or emphasized in this section
- Strategic shifts or competitive positioning not addressed in this text
- Independent auditor for FY 2026 confirmed as KPMG LLP, Auditor Firm ID 185
- Filing mainly references Proxy Statement for detailed governance, executive compensation, and ownership information
Management Discussion & Analysis
- Revenue details not explicitly provided; 2025 Medicaid membership 12.5M, Marketplace 5.5M, Medicare Advantage 1.0M, PDP 8.1M members
- No direct profitability or margin % figures disclosed in the text
- Best segments by membership: Medicaid 12.5M members, weakest not specified
- Capital allocation specifics (buybacks, dividends, capex) not detailed; $1.3B Magellan Rx divestiture gain $269M pre-tax; other divestitures totaling ~$1.6B in proceeds and related gains
- Forward outlook: 2026 Marketplace morbidity expected to increase; medical costs rising accelerated by policy and market changes; OBBBA impacts Medicaid eligibility and funding by 2027; CMS Medicare risk-sharing adjustments and integrated D-SNP requirement beginning 2027
AI summary of the CNC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors since Centene’s 2025 Form 10-K
- Carried-forward risks remain applicable, but specific categories are not detailed in this filing excerpt
Management Discussion & Analysis
- Revenue $50.647B, up 2% YoY from $49.690B
- HBR 92.7% vs 92.7% YoY, SG&A ratio 7.2% vs 7.0%
- Medicare strongest: revenue $11.263B, up 20%; Commercial weakest, revenue $8.700B, down 21%
- Operating cash flow used $3.7B in Q3, driven by pass-through payment timing
- Outlook: elevated medical-cost trend, Medicaid redeterminations, Marketplace membership declines and regulatory uncertainty
AI summary of the CNC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for the period ended September 30, 2026 announced October 27, 2026
- Full financial results available in Exhibit 99.1, the key source for revenue, earnings and guidance details
Item EX-99.1: Item EX-99.1
- Q3 revenue $50.6B, premium revenue $45.1B, up 0.5% year over year
- Adjusted EPS $0.58 despite GAAP loss $(0.14), with adjusted SG&A ratio improving to 6.5%
Item 8.01: Other Events
- Centene plans to redeem all remaining $568.664 million of 4.25% notes on October 23, 2026
- Redemption price: 100% of principal plus accrued interest through October 22, 2026
Item 7.01: Regulation FD Disclosure
- Management reaffirmed 2026 GAAP diluted EPS guidance above $3.11
- Adjusted diluted EPS guidance reaffirmed above $4.80 for full-year 2026
AI summaries of CNC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CNC
Don't miss the next CNC filing
- Alerts as it files. A push when CNC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CNC, by share count.
- Ask anything. An AI agent that reads every CNC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Carson Michael A | F | Oct 15, 2026 | 7,130 | $70.16 |
| EPPINGER FREDERICK H | A | Sep 30, 2026 | 864 | - |
| COUGHLIN CHRISTOPHER J | A | Sep 30, 2026 | 583 | - |
| Samuels Theodore R. II | A | Sep 30, 2026 | 583 | - |
| Tyler Lauren M | A | Sep 30, 2026 | 482 | - |
| TANJI KENNETH | A | Sep 30, 2026 | 603 | - |
| PIENKOS THEODORE J | F | Sep 15, 2026 | 1,092 | $69.41 |
| KOSTER CHRISTOPHER | Sell | Aug 26, 2026 | 56,500 | $66.90 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $145.5B | $174.6B |
| Gross Profit | - | $17.1B | $14.2B |
| Operating Income | - | $3.2B | -$7.6B |
| Net Income | - | $3.3B | -$6.7B |
| Gross Margin | - | 11.7% | 8.1% |
| Op. Margin | - | 2.2% | -4.4% |
| Net Margin | - | 2.3% | -3.8% |
| Balance Sheet | |||
| Total Assets | $84.6B | $82.4B | $76.7B |
| Equity | - | $26.4B | $20.0B |
| ROE | - | 12.5% | -33.4% |
| Per Share | |||
| EPS | - | $6.31 | $-13.53 |
| Cash Flow | |||
| Operating CF | - | $154.0M | $5.1B |
| CapEx | $799.0M | $644.0M | $767.0M |
Source: XBRL data in Centene Corporation (CNC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CNC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $15.07B |
| Q2 2026 | 39 | $15.16B |
| Q1 2026 | 39 | $7.64B |
| Q4 2025 | 36 | $9.97B |
| Q3 2025 | 37 | $8.41B |
| Q2 2025 | 37 | $12.13B |
| Q1 2025 | 33 | $10.84B |
| Q4 2024 | 31 | $9.81B |
- BlackRock+3.30M (+8%)
- AQR Capital Management+2.72M (+9%)
- Invesco Ltd+2.43M (+22%)
- Renaissance Technologies LLC+1.73M (+79%)
- State Street Corp+1.13M (+5%)
- D.E. Shaw & Co−2.32M (-45%)
- Two Sigma Investments−852.3K (-13%)
- Millennium Management−682.8K (-43%)
- T. Rowe Price Group−680.8K (-8%)
- Citadel Advisors LLC−531.9K (-53%)
- Blackstone Group+3.7K
- FMR LLC (Fidelity)−2.63M
- Marex Group plc−7.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 290 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CNC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 10-Q | Oct 27, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 15, 2026 | - | - | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 10-Q | Jul 28, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
Related Health Care companies
- ALHC · Alignment Healthcare, Inc.Hospital & Medical Service Plans
- CI · CignaHospital & Medical Service Plans
- CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DEHospital & Medical Service Plans
- ELV · Elevance HealthHospital & Medical Service Plans
- HUM · HumanaHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
CNC SEC filings: frequently asked questions
Are CNC insiders buying or selling?
In the last 90 days, Centene Corporation (CNC) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $3.8 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CNC stock?
As of September 30, 2026, the largest Centene Corporation (CNC) holders among the 13F filers tracked by SignalX were BlackRock ($2.8 billion), Vanguard Capital Management LLC ($2.0 billion), AQR Capital Management ($1.9 billion), State Street Corp ($1.4 billion), Vanguard Portfolio Management LLC ($1.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CNC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Centene Corporation (CNC) reported revenue of $174.6 billion (up 20.0% from FY2024) and a net loss of $6.7 billion. Diluted EPS was -$13.53. The figures come from the XBRL data in the 10-K.
What are the main risks in CNC's latest 10-K?
In the 10-K filed February 17, 2026, Centene Corporation (CNC) flagged: CMS audit intensification risk with expanded risk adjustment data validation audits since 2025, potentially causing premium refunds and reducing revenue materially. Texas and Georgia Medicaid reprocurement loss risk, involving protests due to unsuccessful bidding, threatening contract renewals and associated revenues. (AI summary of the Risk Factors section.)
What did CNC report in its latest 8-K?
Centene Corporation (CNC) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for the period ended September 30, 2026 announced October 27, 2026.
What are the latest CNC SEC filings?
Centene Corporation (CNC) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on October 15, 2026.
What is CNC's SEC CIK number?
Centene Corporation (CNC)'s SEC Central Index Key (CIK) is 1071739. EDGAR lists every CNC filing under that number.
Ask anything about CNC
The research agent reads CNC's filings, financials, insider trades and 13F holders, then answers with sources.